Stem Cell Mobilization In Multiple Myeloma Therapeutics
1. Aphexda patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12257285 | AYRMID PHARMA | Composition of BL-8040 |
Dec, 2041
(15 years from now) | |
| US12268725 | AYRMID PHARMA | Composition of BL-8040 |
Dec, 2041
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 08, 2028 |
| Orphan Drug Exclusivity(ODE-442) | Sep 08, 2030 |
Drugs and Companies using MOTIXAFORTIDE ACETATE ingredient
NCE-1 date: 09 September, 2027
Market Authorisation Date: 08 September, 2023
Dosage: POWDER
More Information on Dosage
APHEXDA family patents
